Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
Titel:
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
Auteur:
Long, G.V. Arance, A. Mortier, L. Lorigan, P. Blank, C. Mohr, P. Schachter, J. Grob, J.-J. Lotem, M. Middleton, M.R. Neyns, B. Steven, N. Ribas, A. Walpole, E. Carlino, M.S. Lebbe, C. Sznol, M. Jensen, E. Leiby, M.A. Ibrahim, N. Robert, C.
Verschenen in:
Annals of oncology
Paginering:
Jaargang 33 () nr. 2 pagina's 204-215
Jaar:
2022
Inhoud:
Uitgever:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, The Author(s)